Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Gross Profit (2019 - 2021)

VYNE Therapeutics (VYNE) has disclosed Gross Profit for 3 consecutive years, with -$630000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Gross Profit fell 116.79% year-over-year to -$630000.0, compared with a TTM value of -$2.4 million through Dec 2021, down 112.33%, and an annual FY2021 reading of -$2.4 million, down 112.33% over the prior year.
  • Gross Profit was -$630000.0 for Q4 2021 at VYNE Therapeutics, up from -$916000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $11.5 million in Q2 2020 and bottomed at -$916000.0 in Q3 2021.
  • Average Gross Profit over 3 years is $1.9 million, with a median of $135000.0 recorded in 2019.
  • The sharpest move saw Gross Profit soared 2679.26% in 2020, then tumbled 131.61% in 2021.
  • Year by year, Gross Profit stood at $135000.0 in 2019, then skyrocketed by 2679.26% to $3.8 million in 2020, then plummeted by 116.79% to -$630000.0 in 2021.
  • Business Quant data shows Gross Profit for VYNE at -$630000.0 in Q4 2021, -$916000.0 in Q3 2021, and -$500000.0 in Q2 2021.